INmune Bio announces publication of data on INKmune Primed NK cells
INmune Bio announced that the peer-reviewed open access scientific journal PLOS ONE published an article titled: "Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures," summarizing the different effects between NK cell activation in response to tumor cells and cytokine-mediated activation. Co-authored by Dr. Mark Lowdell, Chief Scientific Officer and co-founder at INmune Bio, the paper defines the response of natural killer cells following their encounters with tumor cells and provides insight into tumor-specific NK cell responses; helping the transition toward harnessing their therapeutic potential in cancer. The paper identifies a unique signaling "fingerprint" expressed by NK cells after binding to CTV-1 tumor cells, which is the parent clone of INmune Bio's own INB16 cells. Through these observational data, researchers are able to use that knowledge to apply the strategy to build immunotherapy treatments. Priming NK cells with controlled exposure to tumor cells - which is the mechanism of action of INKmune - in the patient is potentially more effective against cancer targets with potentially fewer side effects than the administration of cytokines such as IL-2 or IL-15.